Patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer who have had a complete or partial response to platinum-based chemotherapy can benefit from Niraparib. It is also beneficial for patients with certain genetic mutations, such as BRCA1 and BRCA2, which make them more susceptible to DNA repair deficiencies.
